Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OC125F(ab')2-CITCDTPA-153Sm
- Development stage
- Preclinical
- Lead developer
- Inserm
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
OC125F(ab')2-CITCDTPA-153Sm is a **radiolabeled monoclonal antibody fragment** developed for targeted **radioimmunotherapy of ovarian cancer**. The drug consists of: - the **F(ab')2 fragment of the OC125 monoclonal antibody** (which targets the CA125 antigen commonly expressed on ovarian tumor cells), - **CITCDTPA** as a chelating agent (6-p-isothiocyanatobenzyl diethylene triamine penta-acetic acid), - **samarium-153 (153Sm)**, a beta-emitting radioisotope for cytotoxic irradiation. This immunoconjugate is designed to selectively localize radiation to CA125-expressing ovarian cancer cells via the antibody fragment, while CITCDTPA enhances the stability of radiometal binding compared to alternative chelators. The improved binding stability of 153Sm with CITCDTPA reduces off-target deposition in non-tumor tissues, favoring tumor-to-nontarget tissue ratios and supporting specific antitumor activity[1][5]. Mechanism of action: OC125F(ab')2 binds to the CA125 antigen on ovarian cancer cells, delivering cytotoxic radiation from samarium-153 directly to the tumor, leading to localized cell death.
- Brand names
- OC125F(ab')2-CITCDTPA-153Sm
- Other names
- OC125F(ab')2-CITCDTPA-153Sm
02
Targets
MUC16 (Mucin-16)
Beyond the preview
Go deeper on OC125F(ab')2-CITCDTPA-153Sm.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OC125F(ab')2-CITCDTPA-153Sm.